Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shankar B, Patil"'
Autor:
Dorairaj Prabhakaran, Shankar B. Patil, Kishore Kumar Deepak, Ambuj Roy, Christa Edmin, Ashok Kumar Jaryal, Kalpana Singh, Ambalam M. Chandrasekaran, Sanjay Kinra, Satish G. Patil
Publikováno v:
Circulation. 142
Introduction: Endothelial function and oxidative stress play a vital role in the prognosis following acute myocardial infarction (AMI). We evaluated the effect of Yoga-based Cardiac Rehabilitation (Yoga-CaRe) programme on markers of endothelial funct
Autor:
Heather M Judge, Shankar B. Patil, Sven Nylander, Sheila E. Francis, Robert F. Storey, Laura E. Jackman
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 30:2385-2391
Objective— Our goal was to study the effects of ticagrelor on murine platelet function and thrombosis and characterize the time course of P2Y 12 inhibition required to inhibit neointima formation following vascular injury. Methods and Results— Mi
Autor:
Richard C. Becker, Dominick J. Angiolillo, Bhaloo Desai, Robert F. Storey, Rosemary Ecob, Lars Wallentin, Shankar B. Patil, Håkan Emanuelsson, Steen Husted, Christopher P. Cannon
Publikováno v:
Journal of the American College of Cardiology. 56:1456-1462
Objectives The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes. ...
Autor:
Shankar B. Patil, Robert J. Buckland, Robert F. Storey, Joseph A. Jakubowski, Heather M Judge
Publikováno v:
Journal of Thrombosis and Haemostasis. 8:1820-1827
The thienopyridine P2Y(12) receptor antagonist clopidogrel reduces the risk of arterial thrombosis and individual pharmacodynamic responses to clopidogrel are believed to reflect the levels of active metabolite (AM) generated. Rifampicin increases th
Autor:
Shankar B. Patil, Arun Karunakaran, Gary Ledley, Tania Gesheff, Mark J. Antonino, Drew A. Purdy, Renli Teng, Cheryl Wei, Paul A. Gurbel, Vance Wilson, Dean J. Kereiakes, Udaya S. Tantry, Kevin P. Bliden, Kathleen Butler, Robert F. Storey, Cordel Parris
Publikováno v:
Circulation. 120:2577-2585
Background— Ticagrelor is the first reversibly binding oral P2Y 12 receptor antagonist. This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes)
Autor:
Shankar B. Patil, K.E. Norman, Robert F. Storey, Sven Nylander, D.J. Crosdale, Sheila E. Francis, S.J. Robins
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:P-W
Autor:
Robert F, Storey, Dominick J, Angiolillo, Shankar B, Patil, Bhaloo, Desai, Rosemary, Ecob, Steen, Husted, Hakan, Emanuelsson, Christopher P, Cannon, Richard C, Becker, Lars, Wallentin
Publikováno v:
Journal of the American College of Cardiology. 56(18)
The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes.The PLATO study demonstrated superiority of ticagrelor over clopi
Autor:
Robert F, Storey, Kevin P, Bliden, Shankar B, Patil, Arun, Karunakaran, Rosemary, Ecob, Kathleen, Butler, Renli, Teng, Cheryl, Wei, Udaya S, Tantry, Paul A, Gurbel
Publikováno v:
Journal of the American College of Cardiology. 56(3)
ObjectivesWe prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind, Double-Dummy Paral